Results 101 to 110 of about 3,654 (190)

Sofosbuvir–velpatasvir in children 3–17 years old with hepatitis C virus infection

Background: The safety and efficacy of sofosbuvir-velpatasvir in children aged 3-17 years with chronic hepatitis C virus (HCV) infection of any genotype were evaluated. Methods: In this Phase 2, multicenter, open-label study, patients received once daily
Osinusi, Anu, de Jong, Jan, Jonas, Maureen M., Leung, Daniel H., Verucchi, Gabriella, Karnsakul, Wikrom, Schwarz, Kathleen B., Parhy, Bandita, Kersey, Kathryn, Murray, Karen F., Lin, Chuan‐Hao, Narkewicz, Michael R., Sokal, Etienne, Rao, Girish S., Shao, Jiang, Wen, Jessica, Bansal, Sanjay, Balistreri, William F., Mangia, Alessandra, Whitworth, Suzanne, Romero, Rene, Rosenthal, Philip, Gonzalez‐Peralta, Regino P.   +22 more
core   +1 more source

Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen

, 2017
UNLABELLED: The optimal retreatment strategy for patients chronically infected with hepatitis C virus who experience virologic failure after treatment with direct-acting antiviral-based therapies remains unclear.
Gane, EJ, Hinestrosa, F, Huang, KC, McHutchison, JG, Davis, MN, Dvory-Sobol, H, Sulkowski, MS, Morelli, G, Shiffman, ML, Etzkorn, K, Osinusi, A, Stedman, CAM, Thompson, AJ, McNally, J, Brainard, DM   +14 more
core   +1 more source

Analysis of the susceptibility of refractory hepatitis C virus resistant to nonstructural 5A inhibitors

Scientific Reports
Resistance-associated substitutions (RASs) of hepatitis C virus (HCV) affect the efficacy of direct-acting antivirals (DAAs). In this study, we aimed to clarify the susceptibility of the coexistence of nonstructural (NS) 5A Q24K/L28M/R30Q (or R30E)/A92K ...
Ai Toyodome, Seiichi Mawatari, Hiromi Eguchi, Midori Takeda, Kotaro Kumagai, Ohki Taniyama, Sho Ijuin, Haruka Sakae, Kazuaki Tabu, Kohei Oda, Masanori Ikeda, Akio Ido   +11 more
doaj   +1 more source

Assessing the Frequency of Cytopenias in Patients with Hepatitis C Therapy: An Analytical Cross-Sectional Study

Journal of Gandhara Medical and Dental Sciences
OBJECTIVES This study aimed to determine the frequency of cytopenias among patients receiving hepatitis C therapy and to examine their relationship with different treatment regimens METHODOLOGY This analytical cross-sectional study was conducted ...
Shadman Ahmad Jan, Naveed Iqbal, Ilyas Muhammad, Zahid Ullah, Ijaz Hussain   +4 more
doaj  

Method development and validation of a new RP-UFLC method for the simultaneous estimation of Sofosbuvir and Velpatasvir in tablet dosage form using an internal standard

Sofosbuvir is an anti-viral drug used for the treatment of chronic hepatitis C virus infection and Velpatasvir is also an anti-viral drug used for the inhibition of hepatitis C virus and both the drugs acts directly.
Priyanka Vallabh Deulkar, Mukthinuthalapati Mathrusri Annapurna   +1 more
core  

Repurposing antiviral drugs targeting RNA viruses: A focus on the fusion protein of human metapneumovirus. [PDF]

North Clin Istanb
Aras M, Yayintas OT.
europepmc   +1 more source

Potential Drug Interactions in Psychiatric Patients Undergoing Pangenotypic Therapy for Hepatitis C Virus Infection. [PDF]

Pharmaceuticals (Basel)
Dybowska D, Pawłowska M, Kozielewicz D.
europepmc   +1 more source

Histopathological features and eight-week split-tablet sofosbuvir/velpatasvir treatment in young children with acute hepatitis C: a case-series study. [PDF]

BMC Infect Dis
Pan YJ, Chen RY, Ai YQ, Zeng QL.
europepmc   +1 more source

Identification of Candidate Inhibitors to SARS-CoV-2's Enzymes and Potential Disruptors of Its Structural Proteins' Interactions. [PDF]

Adv Biomed Res
Mohammadian A, Jadaliha M, Imanpour A, Pourvali Moghadam H, Jahangir A.   +4 more
europepmc   +1 more source

Sofosbuvir, velpatasvir and voxilaprevir combination therapy for treating patients with hepatitis C virus infection

, 2018
Hepatitis C virus (HCV) is a significant public health burden worldwide, owing in large part to ineffective and poorly tolerated treatments. The antivirals have evolved over time to become more effective and better tolerated with cure rates increasing ...
Summers, Bryant B
core